Catalent's Fast Dissolve Technology Used for Allergy Immunotherapy Treatment - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Catalent's Fast Dissolve Technology Used for Allergy Immunotherapy Treatment

When Danish pharmaceutical company ALK-Abelló A/S wanted to find a safe, effective delivery method for its Grazax allergy immunotherapy treatment, it applied Catalent’s proprietary Zydis® Bio fast dissolve technology, a unique, freeze-dried oral solid dosage form that dissolves instantly in the mouth. Allergy injection-based therapy had previously remained unchanged for 100 years, requiring monthly sub-cutaneous injection in a clinic.  Catalent’s Zydis Bio technology allowed ALK to successfully launch Grazax as the first “patient friendly” allergen immunotherapy. Administered daily at home, Grazax demonstrated improved tolerability over traditional treatments and delivered increased patient preference and compliance.

With more than 20 products launched in 50 countries, Catalent’s Zydis Fast Dissolve technology continues to be the world’s best in class, orally disintegrating tablet (ODT) technology. Catalent’s Zydis team is highly trained and offers feasibility testing as well as support across the entire product lifecycle. Whether a company is considering an ODT to enhance pharmacokinetics through pre-gastric absorption, looking for a way to improve patient compliance or seeking a marketing advantage for a valued brand, Zydis fast dissolve can help enhance investment value and accelerate a product’s potential.

Catalent Pharma Solutions


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here